New Duoprl Respules (2.5ml Each)
By Duoprl
Rx
5 Respules in a Packet

Composition
Levosalbutamol(1.25mg) + Ipratropium(500mcg)

Manufacturer - Pristine Pearl Pharma Pvt Ltd
Palepu Palladium, 1st Floor, S.Puram Bypass Coimbatore - 641001

Expires on or after
July, 2025

liver
Limited information is available regarding the use of New Duoprl Respules (2.5ml Each) in patients with liver impairment. It is essential to consult your doctor if you have any concerns about your liver health. Your doctor will assess the potential risks and benefits before prescribing this medication. No specific interactions with the liver have been established at this time. If you have liver issues, seeking advice from your healthcare provider is crucial to ensure safe use of New Duoprl Respules (2.5ml Each).

kidney
Limited info on New Duoprl Respules (2.5ml Each) in kidney-impaired patients. Consult doctor regarding concerns. Benefits vs. risks considered before prescribing.

alcohol
Avoid alcohol while taking New Duoprl Respules (2.5ml Each) due to increased drowsiness risk. Combining alcohol with this medication may lead to unwanted side effects or increased alcohol sensitivity.

driving
Duosules-Neo 500/1.25 Respules may lead to blurred vision or dizziness. If these effects occur, refrain from driving.

pregnancy
New Duoprl Respules (2.5ml Each) may be unsafe for use during pregnancy. Animal studies show potential harm to the baby. Consult your doctor for a thorough evaluation of benefits and risks before use. Limited human studies are available on its safety during pregnancy.

breastfeeding
New Duoprl Respules (2.5ml Each) may be safe for breastfeeding, based on limited data. It is advisable to consult a doctor for guidance on its use during breastfeeding. Further research on Duosules-Neo 500/1.25 Respules and breastfeeding is recommended.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | RESPIRATORY |
Action Class | - |
₹93.5
Inclusive of all taxes
Content verified by

Dr. Upasana Bhatia
MBBS - General Medicine
Last update on 01-Oct-2024